Search results for "Clear cell renal cell carcinoma"
showing 10 items of 18 documents
Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.
2016
e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...
Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.
2012
Abstract Aim of the study Papillary renal cell carcinoma (pRCC) is the second most common subtype of RCC after the conventional clear cell type (cRCC). However, its characteristics and prognosis have been less intensively investigated. The aim of our study was to examine the tumour characteristics and long-term prognosis of pRCC compared to clear cell RCC (cRCC). Methods In total, 4941 evaluable patients were subjected to either radical nephrectomy or nephron-sparing surgery for pRCC or cRCC at five centres in Germany (University Hospitals of Hannover, Homburg/Saar, Mainz, Ulm and Marburg) between 1990 and 2010. Results pRCC ( n = 565) and cRCC ( n = 4376) patients were comparable with re…
In the literature: August 2020.
2020
Immune checkpoint inhibitors (ICI) have become a key component of therapy for several solid tumours. In patients diagnosed with advanced clear cell renal cell carcinoma (ccRCC), immunotherapy has always been considered as a treatment option, and anti-PD-1-based therapies are approved in both the frontline and refractory settings. Response to PD-1 blockade has been associated with numerous tumour-intrinsic and microenvironment features. Genetic characterisation of ccRCC has significantly contributed to the knowledge of tumour biology and the mechanisms of disease progression, but the interplay of genomic alterations with patterns of immune infiltration in response to PD-1 blockade remains un…
MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples
2020
Abstract Background The rising incidence of renal cell carcinomas (RCC) constitutes a significant challenge owing to risk of overtreatment. Because aberrant microRNA (miR) promoter methylation contributes to cancer development, we investigated whether altered miR-30a-5p expression associates with DNA promoter methylation and evaluated the usefulness as clear cell RCC (ccRCC) diagnostic and prognostic markers. Methods Genome-wide methylome and RNA sequencing data from a set of ccRCC and normal tissue samples from The Cancer Genome Atlas (TCGA) database were integrated to identify candidate CpG loci involved in cancer onset. MiR-30a-5p expression and promoter methylation were quantitatively a…
Variation in genomic landscape of clear cell renal cell carcinoma across Europe
2014
The incidence of renal cell carcinoma (RCC) is increasing worldwide, and its prevalence is particularly high in some parts of Central Europe. Here we undertake whole-genome and transcriptome sequencing of clear cell RCC (ccRCC), the most common form of the disease, in patients from four different European countries with contrasting disease incidence to explore the underlying genomic architecture of RCC. Our findings support previous reports on frequent aberrations in the epigenetic machinery and PI3K/mTOR signalling, and uncover novel pathways and genes affected by recurrent mutations and abnormal transcriptome patterns including focal adhesion, components of extracellular matrix (ECM) and …
Systematic Comparative Protein Expression Profiling of Clear Cell Renal Cell Carcinoma
2009
Proteome-based technologies represent powerful tools for the analysis of protein expression profiles, including the identification of potential cancer candidate biomarkers. Thus, here we provide a comprehensive protein expression map for clear cell renal cell carcinoma established by systematic comparative two-dimensional gel electrophoresis-based protein expression profiling of 16 paired tissue systems comprising clear cell renal cell carcinoma lesions and corresponding tumor-adjacent renal epithelium using overlapping narrow pH gradients. This approach led to the mapping of 348 distinct spots corresponding to 248 different protein identities. By implementing restriction criteria concernin…
VHL gēna mutācijas gaišo šūnu nieru karcinomas gadījumā
2019
Nieru šūnu karcinoma ir sestais biežāk diagnosticētais audzējs no visām onkoloģiskajām diagnozēm pasaulē. Gaišo šūnu nieru karcinoma ir 65-70% no visiem saslimšanas gadījumiem ar nieru audzējiem. Izmaiņas von Hippel-Lindau (VHL) gēnā, kurš ir visbiežāk mutētais gēns gaišo šūnu nieru karcinomas gadījumā, tiek salīdzinātas starp in vitro audzētām cilvēku nieru proksimālo kanāliņu epitēlija šūnām un gaišo šūnu nieru karcinomas šūnu līnijām un primārajām šunām, kuras iegūtas no gaišo šūnu nieru karcinomas pacientu audiem un blakus esošiem veselajiem audiem. Darba rezultātā tika konstatēts viena nukleotīda polimorfisms pacientu gaišo šūnu nieru karcinomas audos un veselajos audos no VHL gēna izo…
Classification of Renal Cell Carcinoma Based on Morphologic and Cytogenetic Correlations
1995
Typing or classification of renal cell carcinomas — a term introduced by Murphy and Mostofi in 1965 (1) — has been a debatable field since Grawitz (2) introduced the term hypernephroma in 1883. Grawitz postulated a hypernephrogenic origin of renal cancers, whose cells exhibit a light cytoplasm. During recent decades it has become customary to view renal cell carcinoma as a complex entity. Despite support for this idea by the World Health Organization (3) a morphological subtyping of renal cell carcinoma has not been recognized until recently. In 1986 Thoenes et al. (4) proposed a new pathomorphological subtyping of epithelial renal cell tumors, renal cell carcinoma (RCC) and adenoma (RCA), …
Precision sampling fuels precision oncology: an evolutionary perspective.
2021
Intratumor heterogeneity (ITH) develops in malignant tumors. Precision sampling that captures this tumor variability is essential for the implementation of precision oncology. We highlight the necessity to update current sampling protocols and implement a strategy to ensure ITH detection and characterization. A cost-effective strategy for such sampling has been modeled in clear cell renal cell carcinoma (CCRCC).
DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma.
2014
Aberrant HH signaling has proved important in the pathogenesis of several solid cancers. Limited in vitro analyses suggested an oncogenic role for HH in renal cell carcinoma. In this explorative study we sought to validate aberrant HH expression in patients with renal cell carcinoma.A tissue microarray was constructed from 140 radical nephrectomy specimens of patients with clear cell renal cell carcinoma. We performed immunohistochemistry for Ki67 and HH pathway biomarkers, including PTCH1, Smo, SHH, IHH, DHH, Gli1, Gli2 and Gli3. Staining intensity was measured by automated image processing and related to tumor stage and grade. The impact of biomarker expression on cancer specific survival…